{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:35:17Z","timestamp":1786977317450,"version":"build-2736575974"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We conducted a phase 1\/2 study to evaluate the efficacy and safety of carbon ion radiotherapy (C\u2010ion\n                    <jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>\n                    ) with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma. Thirty\u2010three patients were enrolled between April 2010 and March 2014. Treatment consisted of C\u2010ion\n                    <jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>\n                    with concurrent weekly cisplatin at a dose of 40\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    . In the phase 1 component, the total dose was escalated from 68.0\u00a0Gy (relative biological effectiveness [\n                    <jats:styled-content style=\"fixed-case\">RBE<\/jats:styled-content>\n                    ]) to 74.4\u00a0Gy (\n                    <jats:styled-content style=\"fixed-case\">RBE<\/jats:styled-content>\n                    ) to determine the maximum tolerated dose of C\u2010ion\n                    <jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>\n                    . In the phase 2 component, the efficacy and safety of C\u2010ion\n                    <jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>\n                    with concurrent chemotherapy were evaluated using the dose determined in the phase 1 component. The median follow\u2010up duration was 30\u00a0months. Two patients did not receive chemotherapy because of anemia or leukocytopenia immediately prior to commencing treatment; 31 patients were analyzed. None of the patients developed dose\u2010limiting toxicities. The recommended dose (\n                    <jats:styled-content style=\"fixed-case\">RD<\/jats:styled-content>\n                    ) was determined to be 74.4\u00a0Gy (\n                    <jats:styled-content style=\"fixed-case\">RBE<\/jats:styled-content>\n                    ). In the phase 2 component, two patients developed Grade 3\u20134 toxicities in the gastrointestinal tract, due to repeated laser coagulation or peritonitis caused by appendicitis. In the patients treated with the\n                    <jats:styled-content style=\"fixed-case\">RD<\/jats:styled-content>\n                    , the 2\u2010year local control, progression\u2010free survival, and overall survival rates were 71%, 56%, and 88%, respectively. C\u2010ion\n                    <jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>\n                    with concurrent weekly cisplatin was well tolerated in patients with locally advanced uterine cervical adenocarcinoma. Our findings support further investigations into the efficacy of this strategy.\n                  <\/jats:p>","DOI":"10.1002\/cam4.1305","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T01:45:11Z","timestamp":1516153511000},"page":"351-359","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1\/2 clinical trial (Protocol 1001)"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-1922","authenticated-orcid":false,"given":"Noriyuki","family":"Okonogi","sequence":"first","affiliation":[{"name":"National Institute of Radiological Sciences Hospital National Institutes for Quantum and Radiological Science and Technology  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Wakatsuki","sequence":"additional","affiliation":[{"name":"Department of Radiology Jichi Medical University  Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Saitama Medical University International Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Karasawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Tokyo Women's Medical University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kiyohara","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Maebashi Red Cross Hospital  Gunma Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Shiba","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Gunma University Graduate School of Medicine  Gunma Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Gunma University Graduate School of Medicine  Gunma Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Gunma University Graduate School of Medicine  Gunma Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Kamada","sequence":"additional","affiliation":[{"name":"National Institute of Radiological Sciences Hospital National Institutes for Quantum and Radiological Science and Technology  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makio","family":"Shozu","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine Chiba University Graduate School of Medicine  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Working Group of Gynecological Tumors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"645","article-title":"Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix\u2013worldwide","volume":"10","author":"Mathew A.","year":"2009","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"e_1_2_7_3_1","unstructured":"International Agency for Research on Cancer and World Health Organization.2017.Cervical Cancer: Estimated Incidence Mortality and Prevalence Worldwide in 2012. Available from URL:http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx[accessed June 18 2017]."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04646-8"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904153401502"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05965-7"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.197"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.09.018"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4368"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2005.11.014"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.09.017"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.03.004"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.09.040"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605705"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(88)90018-7"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2307\/3579446"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00544-6"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70412-7"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28621"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.10.021"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq053"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.04.047"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.0497"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00318-0"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/60\/8\/3271"},{"key":"e_1_2_7_26_1","unstructured":"NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0 data files.2017. Available from URL:http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html[accessed June 18 2017]."},{"key":"e_1_2_7_27_1","volume-title":"World Health Organization classification of tumours. Pathology and genetics of tumous of the breast and female genital organs","author":"Tavassoli F. A.","year":"2003"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(03)00197-X"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.12.050"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900601)65:11<2507::AID-CNCR2820651120>3.0.CO;2-9"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11371"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.09.001"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-260"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rru085"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrs017"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.02.009"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.1305","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.1305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T23:54:40Z","timestamp":1695772480000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.1305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,17]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/cam4.1305"],"URL":"https:\/\/doi.org\/10.1002\/cam4.1305","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,17]]},"assertion":[{"value":"2017-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}